Yang N - Search Results

1

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Zhou Q, et al. Among authors: yang jj, yang n. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. doi: 10.1016/j.ccell.2021.07.005. Epub 2021 Aug 12. Cancer Cell. 2021. PMID: 34388377 Free article. Clinical Trial.

2

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.

Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, Liu Y, Wang Y, Zhou C. Yang Z, et al. Among authors: yang n. Clin Cancer Res. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310. Epub 2018 Mar 5. Clin Cancer Res. 2018. PMID: 29506987

3

Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation.

Liao D, Yao D, Liu N, Cao L, Xiang D, Yang N, Zhang Y, Jiang W, Zhou C. Liao D, et al. Among authors: yang n. Cancer Chemother Pharmacol. 2018 Sep;82(3):551-559. doi: 10.1007/s00280-018-3642-4. Epub 2018 Jul 23. Cancer Chemother Pharmacol. 2018. PMID: 30039303

4

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Wu YL, Wang CL, Liao ML, Guan ZZ, Gao CY, Lu S, Zhao MF, Wang J, Liu XQ, Yang JJ, Liang J, Mao WM, Han BH, Zhang XC, Song Y, Feng JF, Ma SL, Wu G, Zhou CC, Chen KN, Cheng Y, He Y, Chen C, Wang Q, Lin JZ, Zhu B, Liu YP, Hu Y, Qiao GB, Zhou Q, Song QB, Wu N, Wu L, Huang C, Fu XL, Xiong JP, Hu J, Hu CP, Chang JH, Zhao Q, Zhao J, Zhou PH, Ma ZY, Chen Y, Zhang HL, Yang F, Wang JJ, Pan YY, Yang XN, Fan Y, Liu Z, Fan W, Yang N, Guan YF, Sun H, Zhong WZ. Wu YL, et al. Among authors: yang xn, yang f, yang jj, yang n. Transl Lung Cancer Res. 2018 Jun;7(3):428-436. doi: 10.21037/tlcr.2018.04.15. Transl Lung Cancer Res. 2018. PMID: 30050780 Free PMC article. Review.

5

Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.

Wang Z, Zhang H, Zhou C, Long X, Guan R, Yang N, Zhang Y. Wang Z, et al. Among authors: yang n. Cancer Med. 2019 Apr;8(4):1434-1441. doi: 10.1002/cam4.2014. Epub 2019 Feb 14. Cancer Med. 2019. PMID: 30762300 Free PMC article.

6

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient.

Hu Y, Xiao L, Yang N, Zhang Y. Hu Y, et al. Among authors: yang n. Thorac Cancer. 2019 May;10(5):1252-1255. doi: 10.1111/1759-7714.13015. Epub 2019 Feb 20. Thorac Cancer. 2019. PMID: 30788907 Free PMC article.

7

The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer.

Yang H, Liu L, Zhou C, Xiong Y, Hu Y, Yang N, Qu J. Yang H, et al. Among authors: yang n. Medicine (Baltimore). 2019 Mar;98(12):e14893. doi: 10.1097/MD.0000000000014893. Medicine (Baltimore). 2019. PMID: 30896637 Free PMC article.

8

EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.

Jiang T, Zhang Y, Li X, Zhao C, Chen X, Su C, Ren S, Yang N, Zhou C. Jiang T, et al. Among authors: yang n. Eur J Cancer. 2019 Nov;121:98-108. doi: 10.1016/j.ejca.2019.08.021. Epub 2019 Sep 27. Eur J Cancer. 2019. PMID: 31569068

9

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.

10

Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.

Zeng L, Xiao L, Jiang W, Yang H, Hu D, Xia C, Li Y, Zhou C, Xiong Y, Liu L, Liao D, Guan R, Li K, Wang J, Zhang Y, Yang N, Mansfield AS. Zeng L, et al. Among authors: yang n, yang h. Lung Cancer. 2020 Mar;141:82-88. doi: 10.1016/j.lungcan.2020.01.009. Epub 2020 Jan 13. Lung Cancer. 2020. PMID: 31982639

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,961 results

Search Page

Filters